Share this article
Share this article
MIAMI, Jan. 23, 2021 /PRNewswire/ eMed™, a digital health company democratizing healthcare through digital point-of-care solutions, announced it will begin to administer the FDA-authorized, at-home symptomatic BinaxNOW™ COVID-19 Ag Card rapid home test to 100,000 qualified individuals across the U.S. who order through eMed.com beginning today. These 100,000 individuals will be among the first to use eMed s transformative approach to at-home testing.
(PRNewsfoto/eMed)
At $25 each, the eMed-administered rapid tests are the first virtually guided, at-home tests available and the most affordable testing option on the market with authenticated results automatically reported to public health authorities.